Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Betadex. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TXNRD1 | Q16881 | 6/20 | 0.49 |
| ▸ | TXNRD3 | Q86VQ6 | 6/20 | 0.49 |
| ▸ | TXNRD2 | Q9NNW7 | 6/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betadex SCHEMBL193191 | 0.99 | ALDH1A1 (0.53) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL2229587 | 0.99 | ALDH1A1 (0.53) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL21629653 | 0.90 | ALDH1A1 (0.47) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL23198883 | 0.88 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL29414129 | 0.86 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL23198880 | 0.80 | ALDH1A1 (0.59) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL25413932 | 0.77 | ALDH1A1 (0.80) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL25414284 | 0.77 | ALDH1A1 (0.80) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL8746198 | 0.75 | ALDH1A1 (0.83) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL6516572 | 0.74 | ALDH1A1 (0.80) | ALDH1A1TSHRLMNATDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633679-A1 | PEPTIDE DRUG CONJUGATES | Oncopeptides Innovation AB (SE) | 2025-10-22 | — | — | EP | claimed |
| EP-4620476-A1 | ANTIVIRAL COMPOSITION CONTAINING INCLUSION COMPOUNDS WITH CYCLODEXTRINS AS ACTIVITY MODULATORS AND ANTISEPTIC ACTIVES AND USES THEREOF | Silva, Renata Moisés Iwamizu (BR) | 2025-09-24 | — | — | EP | claimed |
| US-20250288552-A1 | PHARMACEUTICAL COMPOSITIONS OF FUROSEMIDE AND USES THEREOF | SQ INNOVATION AG (CH) | 2025-09-18 | — | — | US | claimed |
| US-12397005-B2 | Pharmaceutical compositions of torsemide and uses thereof | SQ INNOVATION AG (CH) | 2025-08-26 | — | — | US | claimed |
| US-12318363-B2 | Pharmaceutical compositions of furosemide and uses thereof | SQ INNOVATION AG (CH) | 2025-06-03 | — | — | US | claimed |
| US-12042504-B2 | Injectable fosaprepitant composition | SPES PHARMACEUTICALS INC. | 2024-07-23 | — | — | US | claimed |
| WO-2024126423-A1 | LIPID NANOPARTICLES LYOPHILIZATION METHODS AND COMPOSITIONS | Precision NanoSystems ULC (CA) | 2024-06-20 | — | — | WO | claimed |
| WO-2024126845-A1 | PEPTIDE DRUG CONJUGATES | ONCOPEPTIDES INNOVATION AB (SE) | 2024-06-20 | — | — | WO | claimed |
| CN-117899084-A | Pharmaceutical composition, preparation, metolachlor Zong Donggan powder preparation, preparation method and application thereof | 西安泰可益康生物科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-110575762-B | Preparation method of organic alkyl gadolinium aqueous dispersion system | 温州大学新材料与产业技术研究院 | 2024-03-26 | — | — | CN | claimed |
| EP-1789072-A2 | PROPHYLACTIC AND THERAPEUTIC USES OF FGF-20 IN RADIATION PROTECTION | Curagen Corporation (US) | 2007-05-30 | — | — | EP | claimed |
| WO-2006073417-A2 | PROPHYLACTIC AND THERAPEUTIC USES OF FGF-20 IN RADIATION PROTECTION | CURAGEN CORPORATION (US) | 2006-07-13 | — | — | WO | claimed |
| WO-2006055264-A1 | FORMULATIONS, METHODS OF PRODUCTION AND USES OF FGF-20 | CURAGEN CORPORATION (US) | 2006-05-26 | — | — | WO | claimed |
| US-20060094651-A1 | Formulations and methods of production of FGF-20 | CURAGEN CORPORATION | 2006-05-04 | — | — | US | claimed |
| US-20050215473-A1 | Prophylactic and therapeutic uses of FGF-20 in radiation protection | CURAGEN CORPORATION | 2005-09-29 | — | — | US | claimed |
| US-20050164929-A1 | Methods of preventing and treating inflammatory bowel disease | LUPINE LOGIC, INC. (US) | 2005-07-28 | — | — | US | claimed |
| EP-1250925-B1 | Nasal spray containing ondansetron hydrochloride | AHN GOOK PHARMA CO LTD (KR) | 2005-06-15 | — | — | EP | claimed |
| US-20030044356-A1 | Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one) | AHN-GOOK PHARMA CO., LTD (KR) | 2003-03-06 | — | — | US | claimed |
| EP-1250925-A2 | Nasal spray containing ondansetron hydrochloride | AHN-Gook Pharma Co., Ltd. (KR) | 2002-10-23 | — | — | EP | claimed |
| CN-1278269-A | Piperazine-cyclodextrin complexes | DAIICHI PHARMACEUTIAL CO LTD (JP) | 2000-12-27 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164929-A1 | Methods of preventing and treating inflammatory bowel disease | FGF1, FGF2, FABP2 | ALDH1A1 1931/4885TSHR 3937/4885LMNA 4311/4885 |
| US-20050215473-A1 | Prophylactic and therapeutic uses of FGF-20 in radiation protection | FGF1, FGF2, FGF23 | ALDH1A1 396/4885TSHR 639/4885LMNA 4005/4885 |
| US-20060094651-A1 | Formulations and methods of production of FGF-20 | FGF1, FGF2, FGFR1 | ALDH1A1 1587/4885TSHR 1173/4885LMNA 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.